Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 5 · 100%

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 431 participants
High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 0.5 [0.15, 1.62]
1 study · 480 participants
High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.22 [0.97, 1.54]
1 study · 431 participants
High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 1.21 [0.88, 1.65]
1 study · 431 participants
High

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 447 participants
High